FDA approves Roche's Gazyva (obinutuzumab) for certain people with previously treated follicular lymphoma

Roche today announced that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® (rituximab)-containing regimen, or had their follicular lymphoma return after such treatment.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news